DK1944040T3 - Analysefremgangsmåde for Alzheimers sygdom - Google Patents

Analysefremgangsmåde for Alzheimers sygdom

Info

Publication number
DK1944040T3
DK1944040T3 DK07024341.5T DK07024341T DK1944040T3 DK 1944040 T3 DK1944040 T3 DK 1944040T3 DK 07024341 T DK07024341 T DK 07024341T DK 1944040 T3 DK1944040 T3 DK 1944040T3
Authority
DK
Denmark
Prior art keywords
alzheimer
disease
analysis
Prior art date
Application number
DK07024341.5T
Other languages
English (en)
Inventor
David M Holtzman
Ronald Demattos
Kelly R Bales
David J Cummins
Steven M Paul
Original Assignee
Univ Washington
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Lilly Co Eli filed Critical Univ Washington
Priority claimed from EP02766022A external-priority patent/EP1416965B8/en
Application granted granted Critical
Publication of DK1944040T3 publication Critical patent/DK1944040T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
DK07024341.5T 2001-08-17 2002-08-16 Analysefremgangsmåde for Alzheimers sygdom DK1944040T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31322101P 2001-08-17 2001-08-17
US33498701P 2001-10-23 2001-10-23
EP02766022A EP1416965B8 (en) 2001-08-17 2002-08-16 Assay method for alzheimer's disease

Publications (1)

Publication Number Publication Date
DK1944040T3 true DK1944040T3 (da) 2012-10-29

Family

ID=39294145

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07024341.5T DK1944040T3 (da) 2001-08-17 2002-08-16 Analysefremgangsmåde for Alzheimers sygdom

Country Status (7)

Country Link
US (3) US7771722B2 (da)
EP (1) EP1944040B1 (da)
AU (2) AU2002329775C1 (da)
CY (1) CY1113143T1 (da)
DK (1) DK1944040T3 (da)
ES (1) ES2391905T3 (da)
PT (1) PT1944040E (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192898A1 (en) * 2001-08-17 2004-09-30 Jia Audrey Yunhua Anti-abeta antibodies
EP1519740A4 (en) * 2001-08-17 2005-11-09 Lilly Co Eli FASTER IMPROVEMENT OF COGNITION IN DISEASES ASSOCIATED WITH A-BETA
US7771722B2 (en) * 2001-08-17 2010-08-10 Eli Lilly And Company Assay method for alzheimer's disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ES2344645T3 (es) 2003-02-10 2010-09-02 Applied Molecular Evolution, Inc. Moleculas de union al abeta.
EP1766396B1 (en) * 2004-06-07 2010-08-11 Ramot at Tel-Aviv University Ltd. Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation
US9335331B2 (en) * 2005-04-11 2016-05-10 Cornell Research Foundation, Inc. Multiplexed biomarkers for monitoring the Alzheimer's disease state of a subject
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
DK1954718T3 (da) 2005-11-30 2014-12-15 Abbvie Inc Anti-A-globulomer-antistoffer, antigenbindingsgrupper deraf, tilsvarende hybridomer, nucleinsyrer, vektorer, værtsceller, fremgangsmåder til fremstilling af nævnte antistoffer,
EP1976877B2 (en) 2005-11-30 2016-10-05 AbbVie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
MX358175B (es) 2005-12-12 2018-08-08 Ac Immune Sa Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas.
TWI382990B (zh) * 2005-12-12 2013-01-21 Hoffmann La Roche 可變區域抗體之糖化
WO2008011348A2 (en) 2006-07-14 2008-01-24 Ac Immune S.A. Humanized antibody against amyloid beta
WO2008022349A2 (en) * 2006-08-18 2008-02-21 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
KR101735257B1 (ko) * 2007-01-05 2017-05-12 유니버시티 오브 취리히 질환 특이적 결합 분자 및 표적을 제공하는 방법
ES2535641T3 (es) * 2007-01-18 2015-05-13 Eli Lilly & Company Amiloide beta Fab pegilado
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
EP2170389B1 (en) * 2007-06-12 2014-10-29 AC Immune S.A. Humanized antibodies to amyloid beta
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8974791B2 (en) 2007-07-27 2015-03-10 Armagen Technologies, Inc. Methods and compositions for increasing α-L-iduronidase activity in the CNS
CA2701793C (en) 2007-10-05 2017-04-25 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
EP2205631B1 (en) * 2007-10-05 2016-11-23 Genentech, Inc. Methods and compositions for diagnosis and treatment of amyloidosis
EP2949666B1 (en) 2008-12-19 2018-12-19 Biogen International Neuroscience GmbH Human anti-alpha-synuclein antibodies
WO2010108048A2 (en) 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
EP2485761B1 (en) 2009-10-09 2019-02-27 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
CN103179981B (zh) 2010-07-30 2017-02-08 Ac免疫有限公司 安全和功能性的人源化抗β‑淀粉样蛋白抗体
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
PT2723379T (pt) 2011-06-23 2018-11-14 Univ Of Zuerich Moléculas de ligação anti-alfa-sinucleína
EP3711778A1 (en) 2011-12-02 2020-09-23 Armagen, Inc. Methods and compositions for increasing arylsulfatase a activity in the cns
AU2015325043B2 (en) 2014-09-30 2021-02-18 Washington University Tau kinetic measurements
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
EP3034214A1 (en) * 2014-12-19 2016-06-22 Pramet Tools, S.R.O. Drill and drill insert with chipbreaker protrusions
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
EP4074730A1 (en) 2015-06-24 2022-10-19 F. Hoffmann-La Roche AG Anti-transferrin receptor antibodies with tailored affinity
NZ741067A (en) 2015-10-02 2023-07-28 Hoffmann La Roche Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CA3073066A1 (en) 2017-08-22 2019-02-28 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
TW202243690A (zh) 2021-01-11 2022-11-16 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
WO2023150483A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional tau imaging for diagnosing and treating alzheimer's disease

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5278049A (en) 1986-06-03 1994-01-11 Incyte Pharmaceuticals, Inc. Recombinant molecule encoding human protease nexin
FR2608669A1 (fr) 1986-12-19 1988-06-24 Boussois Sa Vitrage pret a sa pose et son procede de fabrication et de fixation
US4933156A (en) * 1987-04-08 1990-06-12 Salutar, Inc. Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
US5837822A (en) 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
EP0802797A1 (en) 1994-02-03 1997-10-29 The Picower Institute For Medical Research Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US20020086847A1 (en) 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
WO1998044955A1 (en) 1997-04-09 1998-10-15 Mindset Ltd. Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof
US6787319B2 (en) 1997-04-16 2004-09-07 American Home Products Corp. β-amyloid peptide-binding proteins and polynucleotides encoding the same
IT1293511B1 (it) 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
US6114113A (en) 1997-08-11 2000-09-05 Chiron Corporation High efficiency genetic modification method
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
DE69942274D1 (de) 1998-05-21 2010-06-02 Univ Tennessee Res Foundation Methoden zur amyloidentfernung mit anti-amyloid-antikörper
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US6582945B1 (en) 1999-06-16 2003-06-24 Boston Biomedical Research Institute Immunological control of β-amyloid levels in vivo
ATE445639T1 (de) 1999-08-04 2009-10-15 Univ Southern California Globularer aufbau vom amyloid-beta- protein und deren verwendungen
IL142948A0 (en) 1999-09-03 2002-04-21 Univ Ramot Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
US6294171B2 (en) 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
WO2001049875A1 (en) 1999-12-30 2001-07-12 Washington University Predictive diagnostic for alzheimer"s disease
CZ306683B6 (cs) 2000-02-24 2017-05-03 Washington University Léčivo pro prevenci nebo léčení preklinické nebo klinické Alzheimerovy nemoci
US20020009445A1 (en) 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
DK1317479T3 (da) 2000-09-06 2009-11-23 Aventis Pharma Sa Fremgangsmåder og sammensætninger for sygdomme, der er associeret med amyloidosis
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
EP1221680A1 (de) 2001-01-09 2002-07-10 Häni- Prolectron AG Verfahren zur Verrechnung einer Leistung durch Erfassung eines Billetts
US7771722B2 (en) * 2001-08-17 2010-08-10 Eli Lilly And Company Assay method for alzheimer's disease
US20040192898A1 (en) * 2001-08-17 2004-09-30 Jia Audrey Yunhua Anti-abeta antibodies
PT1416965E (pt) 2001-08-17 2008-04-01 Lilly Co Eli Método de ensaio para a doença de alzheimer

Also Published As

Publication number Publication date
EP1944040A3 (en) 2008-12-24
US20100279433A1 (en) 2010-11-04
AU2008202875A1 (en) 2008-07-24
US20130230513A1 (en) 2013-09-05
US7771722B2 (en) 2010-08-10
AU2008202875B2 (en) 2010-11-11
EP1944040B1 (en) 2012-08-01
AU2002329775C1 (en) 2011-04-07
PT1944040E (pt) 2012-10-31
CY1113143T1 (el) 2016-04-13
US9453069B2 (en) 2016-09-27
US8444977B2 (en) 2013-05-21
ES2391905T3 (es) 2012-11-30
EP1944040A2 (en) 2008-07-16
AU2002329775B2 (en) 2008-04-03
US20040248197A1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
DK1944040T3 (da) Analysefremgangsmåde for Alzheimers sygdom
NO20026199D0 (no) Forbindelser for behandling av Alzheimers sykdom
DK2211183T3 (da) Fremgangsmåde til diagnosticering og overvågning af Alzheimer's sygdom
DK1303272T3 (da) Benzothiazolderivater til behandling af Alzheimers sygdom og Parkinsons sygdom
IL159563A0 (en) Method for kidney disease detection by protein profiling
NO20052220D0 (no) Fremgangsmater for behandling av Alzheimers sykdom ved anvendelse av antistoffer rettet mot amyloid beta-peptid og preparater derav
NO20035010D0 (no) Fremgangsmåter og blandinger for analysering av proteiner
IS6316A (is) Aðferð til erfðafræðilegra greininga
DK1392287T3 (da) Anvendelse af substituerede azetidinonderivater i behandlingen af Alzheimers sygdom
NO20032007L (no) Radiofarmasöytika for diagnostisering av Alzheimers sykdom
ITMI20010985A0 (it) Farmaci per il morbo di alzheimer
AU2001236592A1 (en) Methods for diagnosis of alzheimer's disease
AU2001273661A1 (en) Methods of screening for alzheimer's disease
IS7163A (is) Aðferðir til meðhöndlunar á lungnasjúkdómi
DK1456404T3 (da) Fremgangsmåde til at bestemme difibrotids biologiske aktivitet
AU2002336843A8 (en) Biopolymer markers predictive of alzheimers disease
ZA200603178B (en) Quick test for the diagnosis of Alzheimer's disease
DE60231875D1 (de) Kartographisches bildsyntheseverfahren
AUPR202400A0 (en) Method of screening for inhibitors of alzheimer's disease
AU2003251962A8 (en) Screening for alzheimer's disease
EP1693671A4 (en) METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE
FR2856409B1 (fr) Methodes de detection de la maladie d'alzheimer
ITMI20010966A0 (it) Metodo per l'analisi cromosomica di piante
FR2826454B1 (fr) Cartes d'analyse
ITMI20031709A1 (it) Metodo per l'individuazione precoce della malattia di alzheimer.